Jiangsu Yabang Johnson & Johnson Pharmaceutical Co., Ltd.

To evaluate the efficacy and safety of clotrimazole lozenges in the treatment of oropharyngeal candidiasis.

Primary objective: To evaluate the bioequivalence of cefdinir tablets (specification: 0.1 g/tablet) from Jiangsu Yabang Johnson Pharmaceutical Co., Ltd. and cefdinir capsules (specification: 0.1 g/capsule, packaged by Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd.) from the licensee LTL Pharma Co., Ltd. in healthy adult subjects after single oral administration in fasting and fed state. Secondary objective: To evaluate the safety of cefdinir tablets in healthy adult subjects.

The purpose of this study is to use indapamide tablets (specification: 2.5 mg) provided by Jiangsu Yabang Johnson Pharmaceutical Co., Ltd. as the test preparation and indapamide tablets (trade name: Natrilix® specification: 2.5 mg) produced by Servier Pharmaceuticals in France as the reference preparation, and to evaluate the bioequivalence of the two in healthy subjects in the fasting state in accordance with the relevant provisions of the bioequivalence test.